Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
Compositions containing a biologically active material and a non-ordered inorganic oxide material are disclosed. Methods of making and using compositions containing a biologically active material and a non-ordered inorganic oxide material are also disclosed.
1. A composition comprising a biologically active material and an inorganic oxide material, wherein the inorganic oxide material comprises a non-ordered porous material comprising:
pores having a mean pore diameter of about 2.5 nm to about 10 nm, as calculated assuming the pores are cylindrical;
pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cc/g or greater; and
a BET surface area, as measured by nitrogen adsorption, of about 300 m 2 /g or greater.
2. The composition according to claim 1 , wherein the pore volume is about 0.6 cc/g or greater.
3. The composition according to claim 1 , wherein the surface area is about 350 m 2 /g or greater.
4. The composition according to claim 1 , wherein (i) the mean pore diameter is about 5.0 nm to about 10.0 nm, (ii) the pore volume is about 0.7 cc/g or greater, and (iii) the surface area is about 400 m 2 /g or greater.
5. The composition according to claim 1 , wherein as the pore volume increases above about 0.5 cc/g, the surface area ranges from (1) a lower surface area amount represented by a sum of 300 m 2 /g plus about 27 m 2 /g per 0.1 cc/g increase in the pore volume above 1.1 cc/g, and (2) an upper surface area amount represented by a sum of 800 m 2 /g plus about 160 m 2 /g per 0.1 cc/g increase in the pore volume above 0.5 cc/g, or as the pore volume increases above about 0.7 cc/g, the surface area ranges from (1) a lower surface area amount represented by a sum of 400 m 2 /g plus about 40 m 2 /g per 0.1 cc/g increase in the pore volume above 1.0 cc/g, and (2) an upper surface area amount represented by a sum of 560 m 2 /g plus about 84 m 2 /g per 0.1 cc/g increase in the pore volume above 0.7 cc/g.
6. The composition according to claim 1 , wherein the non-ordered porous material further comprises a specific surface area is about 500 m 2 /g or greater.
7. The composition according to claim 1 , wherein the in vitro dissolution rate of the biologically active material is at least about 2 times higher than the dissolution rate of the biologically active material in crystalline form.
8. The composition according to claim 1 , wherein said non-ordered porous material have a pore size distribution relative span of at least about 0.4.
9. The composition according to claim 1 , wherein the inorganic oxide material comprises two or more different and distinct types of non-ordered porous material.
10. The composition according to claim 1 , wherein the inorganic oxide material further comprises at least one ordered porous material.
11. The composition according to claim 1 further comprising at least one pharmaceutical dosage formulating ingredient.
12. The composition according to claim 1 , wherein the biologically active material comprises at least one active pharmaceutical ingredient (API).
13. The composition according to claim 1 , wherein the biologically active material comprises ezetimimbe, tadalafil, or fenofibrate.
14. The composition according to claim 1 , wherein the inorganic oxide material comprises silicon oxide.
15. A composition comprising a biologically active material and an inorganic oxide material, wherein the inorganic oxide material comprises two or more different and distinct types of porous material, a first porous material comprising at least one type of non-ordered porous material and a second porous material comprising at least one type of ordered porous material, the non-ordered porous material comprising:
pores having a mean pore diameter of about 2.5 nm to about 10 nm, as calculated assuming the pores are cylindrical;
pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cc/g or greater; and
a BET surface area, as measured by nitrogen adsorption, of about 300 m 2 /g or greater.
16. The composition according to claim 15 , wherein each of the first and second porous materials provide a specific dissolution rate profile for the biologically active material so as to form a composite dissolution rate profile for the biologically active material.
17. The composition according to claim 15 , wherein the in vitro dissolution rate of the biologically active material is at least about 2 times higher than the dissolution rate of the biologically active material in crystalline form or its equilibrium solubility, or the in vitro dissolution rate of the biologically active material is at least about 2 to about 10 times higher than the dissolution rate of the biologically active material in crystalline form.
18. The composition according to claim 15 , wherein said non-ordered porous material have a pore size distribution relative span of at least about 0.4.
19. The composition according to claim 1 , wherein the biologically active material comprises one selected from groups II or IV of the Biopharmaceutics Classification System.
20. The composition according to claim 15 , wherein the biologically active material comprises one selected from groups II or IV of the Biopharmaceutics Classification System.
21. A composition comprising a biologically active material and an inorganic oxide material, wherein the inorganic oxide material comprises a non-ordered porous material comprising:
pores having a mean pore diameter of about 2.5 nm to about 10 nm, as calculated assuming the pores are cylindrical;
pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cc/g or greater; and
a BET surface area, as measured by nitrogen adsorption, of about 300 m 2 /g or greater,
wherein the biologically active material comprises one selected from groups II or IV of the Biopharmaceutics Classification System.
22. A composition comprising a biologically active material and an inorganic oxide material, wherein the inorganic oxide material comprises two or more different and distinct types of porous material, a first porous material comprising at least one type of non-ordered porous material and a second porous material comprising at least one type of ordered porous material, the non-ordered porous material comprising:
pores having a mean pore diameter of about 2.5 nm to about 10 nm, as calculated assuming the pores are cylindrical;
pores having a pore volume, as measured by nitrogen porosimetry, of about 0.5 cc/g or greater; and
a BET surface area, as measured by nitrogen adsorption, of about 300 m 2 /g or greater,
wherein the biologically active material comprises one selected from groups II or IV of the Biopharmaceutics Classification System.